|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Roles of CREB-binding protein (CBP)/p300 in respiratory epithelium tumorigenesis显示文摘CREB 有约束力的蛋白质(CBP ) 和它的相当或相同事物 p300 是涉及细胞的活动的一个宽数组的各种各样的顺序特定的抄写因素的 transcriptionalco 使活跃之物,例如脱氧核糖核酸修理,房间生长,区别和 apoptosis。Severalstudies 建议了 CBP 和 p300 可能被看作瘤压制 ors,与他们是的突出的角色响应各种各样的刺激的不同基因表示模式的跨 coupling。他们主要经由乙酰化施加行动嘘和另外的规章的蛋白质(例如 p53 ) 。在 CBP/p300 功能的主要悖论是他们似乎能够贡献各种各样的反对细胞的进程。呼吸上皮 tumorigenesis 代表一个范围的多步累积的一个复杂过程基因并且 epigenetic 错误。通过激活和压抑的建筑群的交替的形成的 Transcriptionmodulation 是这些精神错乱的最终的收敛点,并且 CBP/p300 在这相互影响代表关键参加者。因此,他们的分子的行动和相互作用的照明能在呼吸上皮 carcinogenesis 为药理学干预揭示新潜在的目标。 | Michalis V Karamouzis Panagiotis A Konstantinopoulos Athanasios G Papavassiliou | 2007 | Cell Research2007，17，4： | 5 |
| 2 | Pancreatic ductal adenocarcinoma: Treatment hurdles, tumor microenvironment and immunotherapy显示文摘Pancreatic ductal adenocarcinoma(PDAC)is one of the most lethal diseases,with an average 5-year survival rate of less than 10%.Unfortunately,the majority of patients have unresectable,locally advanced,or metastatic disease at the time of diagnosis.Moreover,traditional treatments such as chemotherapy,surgery,and radiation have not been shown to significantly improve survival.Recently,there has been a swift increase in cancer treatments that incorporate immunotherapybased strategies to target all the stepwise events required for tumor initiation and progression.The results in melanoma,non-small-cell lung cancer and renal cell carcinoma are very encouraging.Unfortunately,the application of checkpoint inhibitors,including anti-CTLA4,anti-PD-1,and anti-PD-L1 antibodies,in pancreatic cancer has been disappointing.Many studies have revealed that the PDAC microenvironment supports tumor growth,promotes metastasis and consists of a physical barrier to drug delivery.Combination therapies hold great promise for enhancing immune responses to achieve a better therapeutic effect.In this review,we provide an outline of why pancreatic cancer is so lethal and of the treatment hurdles that exist.Particular emphasis is given to the role of the tumor microenvironment,and some of the latest and most promising studies on immunotherapy in PDAC are also presented. | Panagiotis Sarantis Evangelos Koustas Adriana Papadimitropoulou Athanasios G Papavassiliou Michalis V Karamouzis | 2020 | World Journal of Gastrointestinal Oncology2020，12，2： | 4 |
| 3 | Upgraded role of autophagy in colorectal carcinomas显示文摘Autophagy is a basic catabolic process closely asso-ciated with degradation of cellular components. The role of autophagy in colorectal cancer(CRC) remains controversial. The mechanism of autophagy has been identified as protecting mechanism against tumorige-nesis by isolation of damaged organelles or as cytopro-tective provides energy in hypoxic regions of CRC tumors. Mutations in proto-oncogenes, such as RAS and BRAF, have been associated with autophagy initiation through signaling pathways of BRAF/MEK/ERK and PI3 K/AKT/m TOR. A combination therapy of chemotherapeutic agents and autophagy inhibitors such as hydroxychloroquine or immunotherapy might represent a major step that could be evaluated as a putative novel therapeutic strategy in CRC patients. | Evangelos Koustas Panagiotis Sarantis Athanassios G Papavassiliou Michalis V Karamouzis | 2018 | World Journal of Gastrointestinal Oncology2018，10，11： | 3 |
| 4 | Emerging zoonoses and vector-borne infections affecting humans in Europe显示文摘 | Vorou R M Papavassiliou V G Tsiodras S | 2007 | Epidemiol Infect2007，135，8： | 1 |
| 5 | Epigcnomics in respiratory epithelium carcino- genesis: Prevention and therapeutic challenges显示文摘 | Karamouzis M V Konstantinopolos P A Papavassiliou A G | 2007 | Canc- er Treatment Reviews2007，33，3： | 1 |
| 6 | Improving network anomaly detection effectiveness via an integrated multi-metric-multi-link (Ma L) PCA-based approach显示文摘 | CHATZIGIANNAKIS V PAPAVASSILIOU S ANDROULIDAKIS G | 2009 | Security and Communication Networks2009，2，3： | 1 |
| 7 | Net- work anomaly detection and classification via opportunistic sampling显示文摘 | Androulidakis G Chatzigiannakis V Papavassiliou S | 2009 | TEEE Network2009，23，1： | 1 |
| 8 | Post-translational modifications and regulation of the RAS superfamily of GTPases as anticancer targets显示文摘 | Konstantinopoulos P A Karamouzis M V Papavassiliou A G | 2007 | Nat Rev Drug Discov2007，6，7： | 1 |
| 9 | Targeting insulin-like growth factor in breast cancer therapeutics 显示文摘 | KARAMOUZIS M V PAPAVASSILIOU A G | 2012 | Crit Rev Oncol Hematol2012，84，1： | 1 |
| 10 | Percutaneous transluminal angioplasty for critical limb ischaemia in octogenarians and nonagenarians显示文摘 | SALAS C A ADAM D J PAPAVASSILIOU V G | 2004 | Eur J Vasc Endovasc Surg2004，28，2： | 1 |
| 11 | Side effects of antihypertensive treatment with ACE inhibitors 显示文摘 | 'vssoulis G P Karpanou E A Papavassiliou M V | 2001 | American Journal of Hypertension2001，14，4： | 1 |
| 12 | Congenital duplication of the gallbladder 显示文摘 | Safioleas M C Papavassiliou V G Moulakakis K G | 2006 | Am Surg2006，72，3： | 1 |
| 13 | Role of autophagy in cholangiocarcinoma:An autophagy-based treatment strategy显示文摘Cholangiocarcinomas(CCAs)are diverse biliary epithelial tumours involving the intrahepatic,perihilar and distal parts of the biliary tree.The three entirely variable entities have distinct epidemiology,molecular characteristics,prognosis and strategy for clinical management.However,many cholangiocarcinoma tu-mor-cells appear to be resistant to current chemotherapeutic agents.The role of autophagy and the therapeutic value of autophagy-based therapy are largely unknown in CCA.The multistep nature of autophagy offers a plethora of re-gulation points,which are prone to be deregulated and cause different human diseases,including cancer.However,it offers multiple targetable points for designing novel therapeutic strategies.Tumor cells have evolved to use auto-phagy as an adaptive mechanism for survival under stressful conditions such as energy imbalance and hypoxic region of tumors within the tumor microenvir-onment,but also to increase invasiveness and resistance to chemotherapy.The purpose of this review is to summarize the current knowledge regarding the interplay between autophagy and cholangiocarcinogenesis,together with some preclinical studies with agents that modulate autophagy in order to induce tumor cell death.Altogether,a combinatorial strategy,which comprises the current anti-cancer agents and autophagy modulators,would represent a positive CCA patient approach. | Evangelos Koustas Eleni-Myrto Trifylli Panagiotis Sarantis Athanasios G Papavassiliou Michalis V Karamouzis | 2021 | World Journal of Gastrointestinal Oncology2021，13，10： | 1 |
| 14 | 查看详情显示文摘 | Kontos A I Likodimos V Stergiopoulos T Tsoukleris D S Falaras P Rabias I Papavassiliou G Kim D Kunze J Schmuki P | | 0，，： | 1 |
| 15 | Implication of gut microbiome in immunotherapy for colorectal cancer显示文摘Colorectal cancer(CRC) constitutes the third most frequently reported malignancy in the male population and the second most common in women in the last two decades. Colon carcinogenesis is a complex, multifactorial event, resulting from genetic and epigenetic aberrations, the impact of environmental factors, as well as the disturbance of the gut microbial ecosystem. The relationship between the intestinal microbiome and carcinogenesis was relatively undervalued in the last decade. However, its remarkable effect on metabolic and immune functions on the host has been in the spotlight as of recent years. There is a strong relationship between gut microbiome dysbiosis, bowel pathogenicity and responsiveness to anti-cancer treatment;including immunotherapy. Modifications of bacteriome consistency are closely associated with the immunologic response to immunotherapeutic agents. This condition that implies the necessity of gut microbiome manipulation. Thus, creatingan optimal response for CRC patients to immunotherapeutic agents. In this paper, we will review the current literature observing how gut microbiota influence the response of immunotherapy on CRC patients. | Evangelos Koustas Eleni-Myrto Trifylli Panagiotis Sarantis Nikolaos Papadopoulos Georgios Aloizos Ariadne Tsagarakis Christos Damaskos Nikolaos Garmpis Anna Garmpi Athanasios G Papavassiliou Michalis V Karamouzis | 2022 | World Journal of Gastrointestinal Oncology2022，14，9： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员